Oral Prednisolone for Infantile Hemangioma: Efficacy and Safety Using a Standardized Treatment Protocol

被引:26
作者
Greene, Arin K. [1 ]
Couto, Rafael A. [1 ]
机构
[1] Harvard Univ, Sch Med, Childrens Hosp Boston, Dept Plast & Oral Surg, Cambridge, MA 02138 USA
关键词
PNEUMOCYSTIS-CARINII-PNEUMONIA; DOSE CORTICOSTEROID-THERAPY; CUTANEOUS HEMANGIOMAS; PROPRANOLOL TREATMENT; TRIMETHOPRIM-SULFAMETHOXAZOLE; ADRENAL-FUNCTION; ADVERSE EVENTS; MANAGEMENT; STEROIDS; INFANCY;
D O I
10.1097/PRS.0b013e3182221398
中图分类号
R61 [外科手术学];
学科分类号
摘要
Background: The efficacy of oral corticosteroid therapy for problematic infantile hemangioma depends on dosage, duration of treatment, and definition of therapeutic response. The purpose of this study was to determine the efficacy and safety of oral corticosteroid therapy using a standardized treatment protocol. Methods: The study comprised 25 consecutive patients with infantile hemangioma managed with oral prednisolone between 2007 and 2010. All patients were given 3 mg/kg/day for 1 month, followed by a 0.5-ml taper every 2 to 4 weeks. Predictive variables were age at initiation of treatment, sex, location, lesion size, and tumor depth. Treatment response was defined as no response, stabilization, or regression. Rebound growth and drug morbidity were recorded. Results: Tumors primarily affected the cheek (n = 12), orbit (n = 8), nose (n = 2), forehead (n = 2), or neck (n = 1). Treatment was initiated at an average age of 12.1 +/- 7.2 weeks for 32.2 +/- 10.0 weeks. All tumors responded to therapy; 88.0 percent (n = 22) regressed and 12.0 percent (n = 3) stabilized. Age at initiation of treatment, sex, location, lesion size, and tumor depth did not affect treatment response (p = 0.13). Rebound growth occurred in 8.0 percent of infants, and 20.0 percent demonstrated a transient cushingoid appearance. No patients suffered drug morbidity. Conclusions: The administration of oral prednisolone using a standardized protocol of 3 mg/kg given once daily for 1 month, followed by a taper until the infant is 10 months of age, is an effective treatment for infantile hemangioma. Therapy is safe because it is limited to several months and the dosage is continually weaned as the infant gains weight. (Plast. Reconstr. Surg. 128: 743, 2011.)
引用
收藏
页码:743 / 752
页数:10
相关论文
共 62 条
[11]   THE NATURAL HISTORY OF THE STRAWBERRY NEVUS [J].
BOWERS, RE ;
GRAHAM, EA ;
TOMLINSON, KM .
ARCHIVES OF DERMATOLOGY, 1960, 82 (05) :667-680
[12]  
Breur J, 2010, PEDIAT DERMATOL, V28, P169
[13]   Propranolol for Infantile Hemangiomas: Early Experience at a Tertiary Vascular Anomalies Center [J].
Buckmiller, Lisa M. ;
Munson, Patrick D. ;
Dyamenahalli, Umesh ;
Dai, Yuemeng ;
Richter, Gresham T. .
LARYNGOSCOPE, 2010, 120 (04) :676-681
[14]   Patterns of cerebral injury and neurodevelopmental outcomes after symptomatic neonatal Hypoglycemia [J].
Burns, Charlotte M. ;
Rutherford, Mary A. ;
Boardman, James P. ;
Cowan, Frances M. .
PEDIATRICS, 2008, 122 (01) :65-74
[15]   Case report: Treatment failure using propanolol for treatment of focal subglottic hemangioma [J].
Canadas, Karina T. ;
Baum, Eric D. ;
Lee, Stella ;
Ostrower, Samuel T. .
INTERNATIONAL JOURNAL OF PEDIATRIC OTORHINOLARYNGOLOGY, 2010, 74 (08) :956-958
[16]   Growth characteristics of infantile hemangiomas: Implications for management [J].
Chang, Linda C. ;
Haggstrom, Anita N. ;
Drolert, Beth A. ;
Baselga, Eulalia ;
Chamlin, Sarah L. ;
Garzon, Maria C. ;
Horii, Kimberly A. ;
Lucky, Anne W. ;
Mancini, Anthony J. ;
Metry, Denise W. ;
Nopper, Amy J. ;
Frieden, Ilona J. .
PEDIATRICS, 2008, 122 (02) :360-367
[17]  
Chik K. K., 2010, Hong Kong Medical Journal, V16, P341
[18]   CORTICOSTEROIDS AND PEPTIC-ULCER - METAANALYSIS OF ADVERSE EVENTS DURING STEROID-THERAPY [J].
CONN, HO ;
POYNARD, T .
JOURNAL OF INTERNAL MEDICINE, 1994, 236 (06) :619-632
[19]   A NEW CLASS OF STEROIDS INHIBITS ANGIOGENESIS IN THE PRESENCE OF HEPARIN OR A HEPARIN FRAGMENT [J].
CRUM, R ;
SZABO, S ;
FOLKMAN, J .
SCIENCE, 1985, 230 (4732) :1375-1378
[20]  
ENJOLRAS O, 1990, PEDIATRICS, V85, P491